Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Neogen's EPS for the twelve months ending Aug 31, 2026 was -$0.25. For fiscal 2026 it was -$0.04. The highest annual figure on record is $0.60 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$0.04 | – |
| FY2025 | May 31, 2025 | -$5.03 | – |
| FY2024 | May 31, 2024 | -$0.04 | – |
| FY2023 | May 31, 2023 | -$0.12 | -126.7% |
| FY2022 | May 31, 2022 | $0.45 | -21.1% |
| FY2021 | May 31, 2021 | $0.57 | +1.8% |
| FY2020 | May 31, 2020 | $0.56 | -1.8% |
| FY2019 | May 31, 2019 | $0.57 | -5.8% |
| FY2018 | May 31, 2018 | $0.60 | +40.7% |
| FY2017 | May 31, 2017 | $0.43 | +19.4% |
| FY2016 | May 31, 2016 | $0.36 | +6.7% |
| FY2015 | May 31, 2015 | $0.34 | +18.4% |
| FY2014 | May 31, 2014 | $0.28 | +1.3% |
| FY2013 | May 31, 2013 | $0.28 | +21.0% |
| FY2012 | May 31, 2012 | $0.23 | -3.1% |
| FY2011 | May 31, 2011 | $0.24 | +26.3% |
| FY2010 | May 31, 2010 | $0.19 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$0.05 | -129.4% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$0.05 | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$0.08 | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$0.07 | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $0.17 | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$2.82 | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$0.05 | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$2.10 | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$0.06 | -700.0% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$0.02 | -166.7% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$0.01 | -125.0% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$0.02 | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $0.01 | -80.0% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $0.03 | -78.6% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $0.04 | -20.0% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$0.19 | -290.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $0.05 | -68.8% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $0.14 | -6.7% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $0.05 | -58.3% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $0.10 | -33.3% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $0.16 | +6.7% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $0.15 | 0.0% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $0.12 | +9.1% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $0.15 | 0.0% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $0.15 | +7.1% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $0.15 | 0.0% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $0.11 | -12.0% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $0.15 | -3.2% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $0.14 | -3.4% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $0.15 | -9.1% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $0.13 | -21.9% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $0.15 | -6.1% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $0.14 | +26.1% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $0.17 | +37.5% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $0.16 | +60.0% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $0.17 | +50.0% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $0.12 | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $0.12 | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $0.10 | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $0.11 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?